演題抄録

ポスター

開催概要
開催回
第58回・2020年・京都
 

悪性軟部腫瘍に対するピラルビシン・イホスファミド・エトポシド併用療法の治療成績

演題番号 : P-414

[筆頭演者]
齋藤 志朗:1 
[共同演者]
相羽 久輝:1、山田 聡:1、岡本 秀貴:1、林 克洋:2、木村 浩明:2、三輪 真嗣:2、大塚 隆信:3、村上 英樹:1

1:名古屋市立大学・整形外科、2:金沢大学・整形外科、3:東海学園大学・教育学部

 

Background: The standard chemotherapy regimens for soft tissue sarcoma are doxorubicin-based. This phase 2 study aimed to assess the efficacy and safety of pirarubicin, ifosfamide, and etoposide combination therapy for patients with this disease.
Methods: Between 2008 and 2017, 25 patients with soft tissue sarcoma were treated with pirarubicin (30 mg/m2, 2 days), ifosfamide (2 g/m2, 5 days), and etoposide (100 mg/m2, 3 days) every 3 weeks. The primary endpoint was overall response, and the secondary endpoint was adverse events of this regimen.
Results: Response by RECIST criteria to this regimen was 36% PR (n = 9), 36% SD (n = 9) and 28% PD (n = 7). During the treatment phase, frequent grade 3 or worse adverse events were haematological toxicities including white blood cell decreased (96%), febrile neutropenia (68%), anemia (68%), and platelet count decreased (48%). No long-term adverse events were reported during the study period.
Conclusion: This regimen was comparable to previously published doxorubicin-based combination chemotherapy in terms of response rate. Although there were no long lasting adverse events, severe haematological toxicity should be considered.

キーワード

臓器別:骨軟部

手法別:化学療法

前へ戻る